Citadel Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Citadel Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$139K	Sell	45,000 -4,800	-10%	-$11.3K	﹤0.01%	11749
2025 Q4	$75.2K	Buy	+49,800	New	+$118K	﹤0.01%	11836
2025 Q2	–	Sell	-10,500	Closed	-$35.6K	–	13152
2025 Q1	$35.6K	Sell	10,500 -6,500	-38%	-$26.7K	﹤0.01%	12647
2024 Q4	$70K	Buy	+17,000	New	+$67K	﹤0.01%	11969
2024 Q2	–	Sell	-500	Closed	-$1.03K	–	14512
2024 Q1	$1.03K	Buy	500 +100	+25%	+$178	﹤0.01%	14198
2023 Q4	$720	Buy	+400	New	+$556	﹤0.01%	13953
2023 Q2	–	Sell	-5,900	Closed	-$13.9K	–	14529
2023 Q1	$13.9K	Buy	+5,900	New	+$15.8K	﹤0.01%	13336
2022 Q3	–	Sell	-20,000	Closed	-$49K	–	12856
2022 Q2	$49K	Buy	+20,000	New	+$61K	﹤0.01%	11950
2021 Q4	–	Sell	-12,900	Closed	-$80K	–	14007
2021 Q3	$80K	Buy	+12,900	New	+$90.2K	﹤0.01%	13070

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Citadel Advisors's ELDN Position: Q3 2025 in Review

Citadel Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 152,460 shares — an estimated $446K sold.

Citadel Advisors first reported a position in ELDN in Q2 2019 and held it in 12 quarters. The position peaked at $782K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

Citadel Advisors reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 152,460 Eledon Pharmaceuticals shares in Q3 2025, an estimated $446K.
Citadel Advisors first reported a position in Eledon Pharmaceuticals in Q2 2019 and held it in 12 quarters.
Citadel Advisors's Eledon Pharmaceuticals position peaked at $782K in Q4 2024.
83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.